Issue 37, 2025, Issue in Progress

Lysozyme-dequalinium encapsulation in a Zn–Fe LDH–chia seed matrix for enhanced antimicrobial dental therapeutics

Abstract

This study developed a lysozyme–dequalinium chloride-loaded Zn–Fe layered double hydroxide (LDH)–chia seed mucilage matrix for enhanced antimicrobial efficacy and sustained drug delivery. The optimized formulation (15% w/v Zn–Fe LDH–chia seed hybrid) achieved encapsulation efficiencies of 93.30 ± 1.92% (lysozyme) and 88.74 ± 1.71% (dequalinium), with a particle size of 153.77 ± 5.79 nm, PDI of 0.18, and zeta potential of +26.44 ± 1.21 mV, ensuring stability and mucoadhesion. Surface morphology, structure, drug loading, and thermostability were confirmed using various techniques. In vitro release studies showed sustained drug release over 24 h. Antimicrobial assays demonstrated inhibition zones against S. mutans (24.33 ± 2.03 mm), S. aureus (14.67 ± 0.88 mm), S. sobrinus (11.45 ± 0.887 mm), and K. pneumoniae (20.33 ± 2.03 mm). MIC/MBC analysis indicated high susceptibility of K. pneumoniae (MIC = 13.00 ± 2.60 μg mL−1, MBC = 20.83 ± 5.23 μg mL−1, P < 0.001) and S. mutans (MIC = 15.60 ± 1.05 μg mL−1, MBC = 26.07 ± 5.23 μg mL−1, P < 0.01), with S. sobrinus showing moderate sensitivity (MIC = 49.66 ± 4.32 μg mL−1, MBC = 72.93 ± 6.43 μg mL−1). MBC/MIC ratios below 4 confirmed bactericidal action. The formulation reduced S. mutans biofilm formation by 90.1 ± 1.2% at the highest tested concentration. Cytotoxicity evaluation showed a CC50 of 306.6 μg mL−1, demonstrating improved cytocompatibility compared to the free components.

Graphical abstract: Lysozyme-dequalinium encapsulation in a Zn–Fe LDH–chia seed matrix for enhanced antimicrobial dental therapeutics

Article information

Article type
Paper
Submitted
13 Jun 2025
Accepted
30 Jul 2025
First published
29 Aug 2025
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2025,15, 30872-30899

Lysozyme-dequalinium encapsulation in a Zn–Fe LDH–chia seed matrix for enhanced antimicrobial dental therapeutics

S. M. Mahgoub, A. S. Alawam, H. A. Rudayni, A. A. Allam, S. A. A. Abdel Aziz, A. A. Eweis, E. Khaled, R. Shafei, F. Mohamed and R. Mahmoud, RSC Adv., 2025, 15, 30872 DOI: 10.1039/D5RA04212G

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements